Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis AG, looking to position its once-daily Onbrez Breezhaler (indacaterol) to steal market share from the only once-daily bronchodilator approved for chronic obstructive pulmonary disease, Boehringer Ingelheim GMBH/Pfizer Inc.’s Spiriva (tiotropium), released Phase III data from a head-to-head study comparing the two products.

You may also be interested in...

COPD Market Snapshot: Firms Brush Off Near-term Generic Challenges, Focus On Pipelines

Generics are looming for top-selling chronic obstructive pulmonary disease therapies, but Big Pharma continues to see tremendous growth opportunities in the space

Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol

FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.

As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts

The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts